Furthermore, pregnant women with DCM experience more adverse events compared to non-pregnant women [28,31], and this could be partially explained by the increased hemodynamic challenge that occurs in pregnant patients and by the need to discontinue ACE-inhibitors during pregnancy due to their teratogenic effects. The gene discussed is ACE; the disease is familial dilated cardiomyopathy.